logo
Plus   Neg
Share
Email

Lantheus To Acquire Progenics In All-Stock Deal - Quick Facts

Lantheus Holdings, Inc. (LNTH) has agreed to acquire all of the issued and outstanding common shares of Progenics Pharmaceuticals, Inc. (PGNX) stock. Progenics shareholders will receive 0.2502 shares of Lantheus stock for each share of Progenics. The companies had pro forma combined revenue of $370.1 million for the 12 months ended June 30, 2019. The combination is expected to enhance cash flow generation and be accretive to adjusted and reported earnings per share by 2022 and 2023, respectively.

The combined company will be led by Lantheus CEO Mary Anne Heino, and will trade on the NASDAQ under the ticker symbol, LNTH. Robert Marshall Jr. will assume the position of Chief Financial Officer, while John Bolla will serve as Chief Operations Officer. The deal is anticipated to close in the first quarter of 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT